Duchenne regulatory science consortium meeting on disease progression modeling for duchenne muscular dystrophy

members of the Duchenne Regulatory Science Consortium, Imaging-DMD Consortium and the CINRG Investigators

Research output: Contribution to journalArticle

Abstract

Introduction: The Duchenne Regulatory Science Consortium (D-RSC) was established to develop tools to accelerate drug development for DMD. The resulting tools are anticipated to meet validity requirements outlined by qualification/endorsement pathways at both the U.S. Food and Drug Administration (FDA) and European Medicines Administration (EMA), and will be made available to the drug development community. The initial goals of the consortium include the development of a disease progression model, with the goal of creating a model that would be used to forecast changes in clinically meaningful endpoints, which would inform clinical trial protocol development and data analysis. Methods: In April of 2016 the consortium and other experts met to formulate plans for the development of the model. Conclusions: Here we report the results of the meeting, and discussion as to the form of the model that we plan to move forward to develop, after input from the regulatory authorities.

Original languageEnglish (US)
JournalPLoS Currents
Volume8
Issue numberMuscularDystrophy
StatePublished - 2016

Fingerprint

Duchenne Muscular Dystrophy
Clinical Protocols
Disease Progression
United States Food and Drug Administration
Pharmaceutical Preparations
Clinical Trials

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

members of the Duchenne Regulatory Science Consortium, Imaging-DMD Consortium and the CINRG Investigators (2016). Duchenne regulatory science consortium meeting on disease progression modeling for duchenne muscular dystrophy. PLoS Currents, 8(MuscularDystrophy).

Duchenne regulatory science consortium meeting on disease progression modeling for duchenne muscular dystrophy. / members of the Duchenne Regulatory Science Consortium, Imaging-DMD Consortium and the CINRG Investigators.

In: PLoS Currents, Vol. 8, No. MuscularDystrophy, 2016.

Research output: Contribution to journalArticle

members of the Duchenne Regulatory Science Consortium, Imaging-DMD Consortium and the CINRG Investigators 2016, 'Duchenne regulatory science consortium meeting on disease progression modeling for duchenne muscular dystrophy', PLoS Currents, vol. 8, no. MuscularDystrophy.
members of the Duchenne Regulatory Science Consortium, Imaging-DMD Consortium and the CINRG Investigators. Duchenne regulatory science consortium meeting on disease progression modeling for duchenne muscular dystrophy. PLoS Currents. 2016;8(MuscularDystrophy).
members of the Duchenne Regulatory Science Consortium, Imaging-DMD Consortium and the CINRG Investigators. / Duchenne regulatory science consortium meeting on disease progression modeling for duchenne muscular dystrophy. In: PLoS Currents. 2016 ; Vol. 8, No. MuscularDystrophy.
@article{a8b71d09ee824d3fab69840b8c0916f5,
title = "Duchenne regulatory science consortium meeting on disease progression modeling for duchenne muscular dystrophy",
abstract = "Introduction: The Duchenne Regulatory Science Consortium (D-RSC) was established to develop tools to accelerate drug development for DMD. The resulting tools are anticipated to meet validity requirements outlined by qualification/endorsement pathways at both the U.S. Food and Drug Administration (FDA) and European Medicines Administration (EMA), and will be made available to the drug development community. The initial goals of the consortium include the development of a disease progression model, with the goal of creating a model that would be used to forecast changes in clinically meaningful endpoints, which would inform clinical trial protocol development and data analysis. Methods: In April of 2016 the consortium and other experts met to formulate plans for the development of the model. Conclusions: Here we report the results of the meeting, and discussion as to the form of the model that we plan to move forward to develop, after input from the regulatory authorities.",
author = "{members of the Duchenne Regulatory Science Consortium, Imaging-DMD Consortium and the CINRG Investigators} and Jane Larkindale and Richard Abresch and Enrique Aviles and Abby Bronson and Janice Chin and Pat Furlong and Heather Gordish-Dressman and Elizabeth Habeeb-Louks and Erik Henricson and Hans Kroger and Charles Lynn and Stephen Lynn and Dana Martin and Glen Nuckolls and William Rooney and Klaus Romero and Lee Sweeney and Krista Vandenborne and Glenn Walter and Jodi Wolff and Brenda Wong and McDonald, {Craig M.}",
year = "2016",
language = "English (US)",
volume = "8",
journal = "PLoS Currents",
issn = "2157-3999",
publisher = "Public Library of Science",
number = "MuscularDystrophy",

}

TY - JOUR

T1 - Duchenne regulatory science consortium meeting on disease progression modeling for duchenne muscular dystrophy

AU - members of the Duchenne Regulatory Science Consortium, Imaging-DMD Consortium and the CINRG Investigators

AU - Larkindale, Jane

AU - Abresch, Richard

AU - Aviles, Enrique

AU - Bronson, Abby

AU - Chin, Janice

AU - Furlong, Pat

AU - Gordish-Dressman, Heather

AU - Habeeb-Louks, Elizabeth

AU - Henricson, Erik

AU - Kroger, Hans

AU - Lynn, Charles

AU - Lynn, Stephen

AU - Martin, Dana

AU - Nuckolls, Glen

AU - Rooney, William

AU - Romero, Klaus

AU - Sweeney, Lee

AU - Vandenborne, Krista

AU - Walter, Glenn

AU - Wolff, Jodi

AU - Wong, Brenda

AU - McDonald, Craig M.

PY - 2016

Y1 - 2016

N2 - Introduction: The Duchenne Regulatory Science Consortium (D-RSC) was established to develop tools to accelerate drug development for DMD. The resulting tools are anticipated to meet validity requirements outlined by qualification/endorsement pathways at both the U.S. Food and Drug Administration (FDA) and European Medicines Administration (EMA), and will be made available to the drug development community. The initial goals of the consortium include the development of a disease progression model, with the goal of creating a model that would be used to forecast changes in clinically meaningful endpoints, which would inform clinical trial protocol development and data analysis. Methods: In April of 2016 the consortium and other experts met to formulate plans for the development of the model. Conclusions: Here we report the results of the meeting, and discussion as to the form of the model that we plan to move forward to develop, after input from the regulatory authorities.

AB - Introduction: The Duchenne Regulatory Science Consortium (D-RSC) was established to develop tools to accelerate drug development for DMD. The resulting tools are anticipated to meet validity requirements outlined by qualification/endorsement pathways at both the U.S. Food and Drug Administration (FDA) and European Medicines Administration (EMA), and will be made available to the drug development community. The initial goals of the consortium include the development of a disease progression model, with the goal of creating a model that would be used to forecast changes in clinically meaningful endpoints, which would inform clinical trial protocol development and data analysis. Methods: In April of 2016 the consortium and other experts met to formulate plans for the development of the model. Conclusions: Here we report the results of the meeting, and discussion as to the form of the model that we plan to move forward to develop, after input from the regulatory authorities.

UR - http://www.scopus.com/inward/record.url?scp=85010782727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010782727&partnerID=8YFLogxK

M3 - Article

VL - 8

JO - PLoS Currents

JF - PLoS Currents

SN - 2157-3999

IS - MuscularDystrophy

ER -